Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues

May 31, 2022

Lab technician injecting a substance into a vial in a labratory.

Guidance Document

Center for Drug Evaluation and Research

This guidance describes the Food and Drug Administration’s (FDA’s) current recommendations regarding the overall development program to establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.

The recommendations in section III.C., Registrational Trial Considerations, apply to drug product development programs for GnRH analogues in advanced prostate cancer for all dosage forms and routes of administration (e.g., tablets, capsules, injectable suspensions, injectable emulsions, subcutaneous implants). Other sections apply only to extended-release injectable dosage forms.

Download the Final Guidance Document

Final Level 1 Guidance

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.

TAGS: CDER FDA North America GnRH Agency Alerts Final Guidance Regulatory Sciences

Related Articles

Medical device on table
Medical Devices

November 13, 2023

FDA Finalizes the Breakthrough Devices Program Guidance and Reinforces Innovative Medical Device Manufacturers that Help to Address Health Inequities

The FDA's Breakthrough Devices Program is intended to expedite the development of innovative technologies for patients with life-threatening or irreversibly debilitating diseases or conditions. The...

Continue reading the blog post
Computer generated rendering molecules, cells, and DNA structures.
FDA

June 16, 2022

Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies

Guidance Document Draft Guidance for Industry June 2022 This guidance describes a standards recognition program for regenerative medicine therapies (SRP-RMT) at FDA’s Center for Biologics Evaluation...

Continue reading the blog post
Illustration of a magnifying glass enlarging a checklist.
FDA

July 8, 2022

CVM GFI #245 - Hazard Analysis and Risk-Based Preventive Controls for Food for Animals

July 2022 The purpose of this guidance is to help animal food facilities develop a food safety plan that complies with FDA’s Hazard Analysis and Risk-Based Preventive Controls requirements....

Continue reading the blog post